# antibodies .- online.com







Overview

Alternative Name:

Background:

**Image** 



**Publications** 



Go to Product page

Overview	
Quantity:	400 μL
Target:	CDKN3
Binding Specificity:	AA 39-68, N-Term
Reactivity:	Human
Host:	Rabbit
Clonality:	Polyclonal
Conjugate:	This CDKN3 antibody is un-conjugated
Application:	Western Blotting (WB)
Product Details	
Immunogen:	This CDKN3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 39-68 amino acids from the N-terminal region of human CDKN3.
Clone:	RB42328
Isotype:	Ig Fraction
Purification:	This antibody is purified through a protein A column, followed by peptide affinity purification.
Target Details	
Target:	CDKN3

The protein encoded by this gene belongs to the dual specificity protein phosphatase family. It

CDKN3 (CDKN3 Products)

## **Target Details**

was identified as a cyclin-dependent kinase inhibitor, and has been shown to interact with, and dephosphorylate CDK2 kinase, thus prevent the activation of CDK2 kinase. This gene was reported to be deleted, mutated, or overexpressed in several kinds of cancers. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Molecular Weight: 23805

NCBI Accession: NP\_001124323, NP\_005183

UniProt: Q16667

# **Application Details**

Application Notes: WB: 1:1000

Restrictions: For Research Use only

## Handling

Format:	Liquid
Buffer:	Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.
Preservative:	Sodium azide
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage:	4 °C,-20 °C
Expiry Date:	6 months

### **Publications**

Product cited in:

Jiang, Xia, Li, Deng, Zhao, Shi, Wang, Sun: "High expression levels of IKKalpha and IKKbeta are necessary for the malignant properties of liver cancer." in: **International journal of cancer. Journal international du cancer**, Vol. 126, Issue 5, pp. 1263-74, (2010) (PubMed).

Shimada, Miyagawa, Kawashima, Tanaka, Honda, Honda, Tokunaga: "An approach based on a genome-wide association study reveals candidate loci for narcolepsy." in: **Human genetics**, Vol. 128, Issue 4, pp. 433-41, (2010) (PubMed).


Okamoto, Kitabayashi, Taya: "KAP1 dictates p53 response induced by chemotherapeutic

agents via Mdm2 interaction." in: **Biochemical and biophysical research communications**, Vol. 351, Issue 1, pp. 216-22, (2006) (PubMed).

Hsieh, Yao, Lai, Yang: "Transcriptional repression activity of PAX3 is modulated by competition between corepressor KAP1 and heterochromatin protein 1." in: **Biochemical and biophysical research communications**, Vol. 349, Issue 2, pp. 573-81, (2006) (PubMed).

Chinami, Yano, Yang, Salahuddin, Moriyama, Shiroishi, Turner, Shirakawa, Adra et al.: "Binding of HTm4 to cyclin-dependent kinase (Cdk)-associated phosphatase (KAP).Cdk2.cyclin A complex enhances the phosphatase activity of KAP, dissociates cyclin A, and facilitates KAP..." in: **The Journal of biological chemistry**, Vol. 280, Issue 17, pp. 17235-42, (2005) (PubMed).

### **Images**



## **Western Blotting**

**Image 1.** CDKN3 Antibody (N-term) (ABIN1881194 and ABIN2838950) western blot analysis in HepG2 cell line lysates (35  $\mu$ g/lane). This demonstrates the CDKN3 antibody detected the CDKN3 protein (arrow).